Rising and Higher Healthcare Resource Utilization (HCRU) and Costs of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease of Increasing Severity - Results of a US Real-World Analysis

被引：0
|
作者：
Wong, Robert J. [1 ]
Kachru, Nandita [2 ]
Meyer, Nicole [3 ]
Gordon, Stuart C. [4 ]
机构：
[1] Highland Hosp, Alameda Hlth Syst, Div Gastroenterol & Hepatol, Oakland, CA USA
[2] Gilead Sci, Foster City, CA USA
[3] Truven Hlth Analyt, Cambridge, MA USA
[4] Henry Ford Hlth Syst, Detroit, MI USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2268
引用
收藏
页码：1283A / 1284A
页数：2
相关论文
共 50 条
  • [31] ROLE OF PHARMACOTHERAPY IN REAL WORLD PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Eghbali, Shabnam
    Newberry, Carolyn
    Yeung, Michele
    Sharaiha, Reem Z.
    Kumar, Sonal
    GASTROENTEROLOGY, 2021, 160 (06) : S839 - S839
  • [32] High Health-Care Utilization (HCU) and Costs Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients
    Gordon, Stuart
    Fraysse, Jeremy
    Li, Suying
    Ozbay, A. Burak
    Wong, Robert
    DIABETES, 2019, 68
  • [33] MODELING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH) WITH HUMAN MULTI-CELL-LINEAGE LIVER ORGANOIDS
    Zhang, Wenjun
    Park, Yujin
    Thadasina, Deepthi
    Isidan, Abdulkadir
    Bolujo, Ifeoluwa
    Wilmes, Danielle M.
    Farag, Kristine
    Lopez, Kevin
    Cross-Najafi, Arthur A.
    Li, Ping
    Kyritsi, Konstantina
    Kennedy, Lindsey
    Glaser, Shannon S.
    Francis, Heather L.
    Alpini, Gianfranco
    Ekser, Burcin
    HEPATOLOGY, 2022, 76 : S699 - S700
  • [34] Saroglitazar Shows Therapeutic Benefits in Mouse Model of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
    Jain, Mukul R.
    Giri, Suresh R.
    Bhoi, Bibhuti
    Trivedi, Chitrang
    Ranvir, Ramchandra
    Kadam, Shekhar
    Swain, Prabodha
    Patel, Pankaj R.
    DIABETES, 2015, 64 : A503 - A503
  • [35] Innovative Molecular Targets and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 3.0
    Vairetti, Mariapia
    Colucci, Giuseppe
    Ferrigno, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [36] Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
    Vairetti, Mariapia
    Colucci, Giuseppe
    Ferrigno, Andrea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [37] Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system
    Kato, Hiroyuki
    Isaji, Shuji
    Azumi, Yoshinori
    Kishiwada, Masashi
    Hamada, Takashi
    Mizuno, Shugo
    Usui, Masanobu
    Sakurai, Hiroyuki
    Tabata, Masami
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2010, 17 (03) : 296 - 304
  • [38] Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
    Wen, Xuerong
    Wang, Shuang
    Taveira, Tracey H.
    Akhlaghi, Fatemeh
    PLOS ONE, 2021, 16 (09):
  • [39] Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
    Wong, Robert J.
    Kachru, Nandita
    Martinez, Diane J.
    Moynihan, Meghan
    Ozbay, A. Burak
    Gordon, Stuart C.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (10) : 891 - 902
  • [40] Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large US Claims Database
    Allen, Alina M.
    Van Houten, Holly K.
    Sangaralingham, Lindsey R.
    Talwalkar, Jayant A.
    McCoy, Rozalina G.
    HEPATOLOGY, 2018, 68 (06) : 2230 - 2238
12345